23andMe Reports GLP-1 Genetic Response Predictors 23andMe Gilead Expands Tempus AI Real-World Data Deal Tempus AI CareDx wins $45 mln verdict against Natera for false advertising - Reuters — Reuters Companies Natera Illumina Adds Activist to Board, Names Former FDA Chief as Chair - Bloomberg.com — Bloomberg Companies Illumina Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study-3 and Circulating Cell-Free Genome Atlas Substudy 3. — Pubmed GRAIL 23andMe study explains variable results with obesity drugs — Pharmaphorum 23andMe Natera awarded 30% ongoing royalty in MRD patent litigation — Seeking Alpha Ntra Natera Alamar Biosciences, Inc. filed S-1: S-1 — Edgar Fulltext Alamar Biosciences, Inc. Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome — Clinicaltrials National Cancer Institute (NCI) The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets. — Pubmed Foundation Medicine Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction. — Pubmed AstraZeneca Roche to Invest $50 Billion in U.S. Manufacturing, R&D as Tariffs Loom - WSJ — Wsj Topics Roche Holding Top Five Articles on GenomeWeb Last Week: IDT Enters IVD Market, NCCN Update, Endometriosis Dx, More - GenomeWeb — Genomeweb Google Integrated DNA Technologies Press ReleasesPress ReleasesFebruary 9, 202620262026BillionToOne Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, Extending Its Leadership In Setting the New Standard in Prenatal CareLearn More — Ir Billiontoone BillionToOne Press ReleasesPress ReleasesJanuary 15, 202620262026BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across HealthcareLearn More — Ir Billiontoone BillionToOne Guardant sues Tempus AI over DNA-testing patents - Reuters — Reuters Companies Tempus AI Qiagen Partners Sophia Genetics on NGS Kits Sophia Genetics SoftBank Group launches AI healthcare joint venture with Tempus AI - Reuters — Reuters Companies SoftBank Group Roche Pledges $50B U.S. Investment Roche Holding Quest Raises 2025, 2026 Forecasts After Q1 Beat Quest Diagnostics Oxford Nanopore Wins First Diagnostic Approval in Europe Oxford Nanopore Myriad Wins FDA Approval for Ovarian Cancer CDx Myriad Genetics MGI Tech Exits U.S. Citing Geopolitics MGI Tech Illumina Partners Labcorp, Veritas on Clinical Test Distribution Illumina Guardant Owes $83.4M in Patent Verdict, Settles Illumina Guardant Health Lab Industry Weighs Pros and Cons as CMS Ponders Expanding MolDX Program to Address Fraud - 360Dx — 360Dx Google Color Health GRAIL Names Ofman CEO as Ragusa Retires GRAIL Guardant Health Is Said to Decide Against Buying NeoGenomics - Bloomberg — Bloomberg Companies Guardant Health GRAIL Plugs Galleri Into Epic EHR GRAIL Exact Sciences Claims 30% Drop in False Positives Exact Sciences 23andMe Reports GLP-1 Genetic Response Predictors 23andMe Gilead Expands Tempus AI Real-World Data Deal Tempus AI CareDx wins $45 mln verdict against Natera for false advertising - Reuters — Reuters Companies Natera Illumina Adds Activist to Board, Names Former FDA Chief as Chair - Bloomberg.com — Bloomberg Companies Illumina Preclinical circulating tumor DNA shedding duration and prognostic implications of modeling 3669 patients with cancer in the American Cancer Society Cancer Prevention Study-3 and Circulating Cell-Free Genome Atlas Substudy 3. — Pubmed GRAIL 23andMe study explains variable results with obesity drugs — Pharmaphorum 23andMe Natera awarded 30% ongoing royalty in MRD patent litigation — Seeking Alpha Ntra Natera Alamar Biosciences, Inc. filed S-1: S-1 — Edgar Fulltext Alamar Biosciences, Inc. Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome — Clinicaltrials National Cancer Institute (NCI) The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets. — Pubmed Foundation Medicine Longitudinal ultrasensitive ctDNA monitoring for high-resolution lung cancer risk prediction. — Pubmed AstraZeneca Roche to Invest $50 Billion in U.S. Manufacturing, R&D as Tariffs Loom - WSJ — Wsj Topics Roche Holding Top Five Articles on GenomeWeb Last Week: IDT Enters IVD Market, NCCN Update, Endometriosis Dx, More - GenomeWeb — Genomeweb Google Integrated DNA Technologies Press ReleasesPress ReleasesFebruary 9, 202620262026BillionToOne Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, Extending Its Leadership In Setting the New Standard in Prenatal CareLearn More — Ir Billiontoone BillionToOne Press ReleasesPress ReleasesJanuary 15, 202620262026BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across HealthcareLearn More — Ir Billiontoone BillionToOne Guardant sues Tempus AI over DNA-testing patents - Reuters — Reuters Companies Tempus AI Qiagen Partners Sophia Genetics on NGS Kits Sophia Genetics SoftBank Group launches AI healthcare joint venture with Tempus AI - Reuters — Reuters Companies SoftBank Group Roche Pledges $50B U.S. Investment Roche Holding Quest Raises 2025, 2026 Forecasts After Q1 Beat Quest Diagnostics Oxford Nanopore Wins First Diagnostic Approval in Europe Oxford Nanopore Myriad Wins FDA Approval for Ovarian Cancer CDx Myriad Genetics MGI Tech Exits U.S. Citing Geopolitics MGI Tech Illumina Partners Labcorp, Veritas on Clinical Test Distribution Illumina Guardant Owes $83.4M in Patent Verdict, Settles Illumina Guardant Health Lab Industry Weighs Pros and Cons as CMS Ponders Expanding MolDX Program to Address Fraud - 360Dx — 360Dx Google Color Health GRAIL Names Ofman CEO as Ragusa Retires GRAIL Guardant Health Is Said to Decide Against Buying NeoGenomics - Bloomberg — Bloomberg Companies Guardant Health GRAIL Plugs Galleri Into Epic EHR GRAIL Exact Sciences Claims 30% Drop in False Positives Exact Sciences